The 5 GLP-1 Clients You'll Coach (and 2 You Might Not... Yet)

One in eight adults has already taken a GLP-1 drug, and the pipeline keeps growing — your roster has people on semaglutide and tirzepatide whether you’ve asked or not. Most of them didn’t tell you, for the same reason they don’t mention the IBS: they’re braced for a lecture. Don’t give them one. Give them a plan.

This is the same coaching logic as our first 30 days IBS playbook: the medication or the diagnosis is the physician’s lane, but the daily habits that decide whether the outcome is good or ugly are yours. The specific stakes here are muscle. GLP-1 drugs suppress appetite so effectively that the calorie deficit they create can strip away lean mass along with fat — and in some analyses, 25–40% of the weight lost is lean (Bikou et al., Expert Opin Pharmacother, 2024 — https://pubmed.ncbi.nlm.nih.gov/38629387/). The SEMALEAN study confirmed it in the real world: semaglutide reduced fat mass and lean mass with measurable drops in muscle function (Alissou et al., Diabetes Obes Metab, 2026 — https://pubmed.ncbi.nlm.nih.gov/41068996/).

A client who loses 40 pounds on a GLP-1 but loses 12 of it as muscle comes out the other side smaller, weaker, and with a slower metabolism — primed for the next regain. Your job on the roster is to make sure that’s not the story.

What’s actually happening

The mechanism is straightforward and a little brutal. GLP-1 receptor agonists turn down appetite signaling — gastric emptying slows, satiety arrives early, food noise goes quiet. The result is a steep, involuntary calorie deficit that often lands well below what any client would choose to eat voluntarily. And a big deficit without lifting and protein is a recumbency study: the body burns fat, but it also burns muscle, because muscle is expensive to keep when intake collapses.

The interaction between these drugs and training is still being mapped, but the early evidence points one direction: resistance exercise during incretin-based weight loss is the best-supported way to shift the body-composition trade toward keeping muscle (Locatelli et al., Diabetes Care, 2024 — https://pubmed.ncbi.nlm.nih.gov/38687506/), and animal work shows preserving muscle during GLP-1 treatment is biologically possible, not fantasy (Nunn et al., Mol Metab, 2024 — https://pubmed.ncbi.nlm.nih.gov/38218536/).

Why this matters to you specifically

Because the drugs already sorted your client list for you. The person asking about “toning up” while mentioning her appetite vanished in June is a GLP-1 client. So is the guy whose lifts dropped 20% for no reason. You don’t need to become a medication expert — you need to recognize the five situations you’ll actually meet, run the same muscle-protection plan for all of them, and know which two conversations you’re not qualified to have.

What you can do today

The 5 clients you’ll coach:

1. The already-on-it client. She started Wegovy three months ago, is down 15 pounds, and now wants “to not look deflated.” Core plan: protein first (aim toward the higher end — roughly 1.6 g/kg/day is the defensible floor in a hard deficit; see the resistance-training body composition meta-analysis, Health Sci Rep, 2026 — https://pubmed.ncbi.nlm.nih.gov/41870448/), lifting 2–3x per week with real loads, and symptom tracking so her doctor hears about nausea, fatigue, or dizziness from a documented timeline rather than vibes.

2. The yo-yo dieter. Twenty years of 1,200-calorie cycles left her with a low lean-mass baseline and a deep distrust of “just eat less.” A GLP-1 without strength work is her sixth diet. With strength work, it’s the first intervention that also rebuilds what the diets stripped. Frame the lifting as non-negotiable from day one — this client skips it by default.

3. The perimenopausal client. She’s 46, the weight came on fast, and her doctor offered a GLP-1. Muscle loss is already accelerating at her age; layering a powerful appetite suppressant on top without a lifting program accelerates it further. Same plan as above, plus the hormone-context from strength training after 40 — and slow, deliberate loss targets, not crash speed.

4. The appetite-driven client. This is the client GLP-1s genuinely help — hunger and food noise were the mechanism behind her weight gain, not discipline. Her risk profile is different: as the appetite drops, her protein intake often collapses with it, because nothing sounds good. The coaching skill here is meal structure that doesn’t depend on appetite: protein-first eating order, scheduled intake, liquid options when solid food is a no.

5. The metabolic client. Prediabetic, elevated A1c, doctor recommended it. This is the cleanest case — the drugs have genuine metabolic indication, and the strong efficacy across agents (2026, Diabetes Obes Metab — https://pubmed.ncbi.nlm.nih.gov/41872986/; and if her doctor is weighing options, our semaglutide vs tirzepatide comparison covers the head-to-head evidence). Your job is the same muscle protocol plus coordination: keep the physician in the loop on training intensity, especially early.

The 2 you refer out (for now):

1. The client with a disordered-eating history. A drug that annihilates appetite cues is a genuinely dangerous tool for someone whose recovery depends on relearning them. This is not a coaching problem, and “she seems fine now” is not a safety system. Referral first, training after her clinical team signs off.

2. The client medicating without oversight. Gray-market semaglutide, “research peptides,” med-spa dosing with no follow-up — if no physician is tracking side effects, labs, or bone health (and long-term users need that monitoring; see Calcif Tissue Int, 2024 — https://pubmed.ncbi.nlm.nih.gov/37999750/), you’re coaching on top of an unmonitored intervention. Require the physician relationship before you require the squat rack.

What to stop doing

Stop treating GLP-1 clients as “cheating.” The drugs are a medical intervention prescribed by a doctor; the client in front of you needs a program, not a moral position. Stop defaulting to light dumbbells and “just keep moving” — the evidence favors progressive loading. And stop ignoring the bone question: rapid weight loss on these drugs has skeletal consequences worth monitoring (Anastasilakis et al., Diabetes Obes Metab, 2025 — https://pubmed.ncbi.nlm.nih.gov/40555693/), which we covered in depth in the GLP-1 bone and muscle loss guide — and heavy lifting is the cheapest osteogenic signal there is.

The supplement / product question

Protein is the one supplement with a real job here, and the practical problem is appetite: most GLP-1 clients can’t face a chicken breast at 40% of their old food drive. That’s why purpose-built options exist:

GLP-1 Protein Powder — 10g whey protein, vanilla — small-portion format designed for suppressed appetites. Mechanism-honest: it helps hit protein floors; it doesn’t preserve muscle by itself.

Transparent Labs Grass-Fed Whey Protein — clean isolate for clients who want minimal ingredients per calorie. Disclosure: this post contains affiliate links; we may earn a commission at no extra cost to you.

Optimum Nutrition Gold Standard Whey — the reliable budget-per-gram pick for clients who just need a shaker they’ll actually use daily.

What we still don’t know

We still don’t know how much of GLP-1 muscle loss is preventable with training and protein in the real world — the trial arms that test lifting protocols inside GLP-1 treatment are small and recent, and nobody has published the definitive “train like this, lose almost no lean mass” protocol. Until it exists, the 1.6 g/kg protein floor and 2–3 lifting sessions a week aren’t dogma; they’re the best currently standing bridge between the body your client has and the one the drug promised.

Save this for the client who mentions her appetite disappeared — the conversation starts there, not with a lecture.